DLBCL

In an interview with Targeted Oncology, John M. Burke, MD, discussed the ongoing phase Ib First-MIND clinical trial of tafasitamab in combination with R-CHOP with or without lenalidomide as treatment of patients with newly diagnosed diffuse large B-cell lymphoma.

Elise Chong, MD, discusses the rationale for conducting a 4-year analysis of tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Rajat Bannerji, MD, PhD, discussed the safety and efficacy findings from the phase I trial of a bispecific antibody in patients with heavily pretreated NHL, including cohorts of patients with follicular lymphoma and diffuse large B-cell lymphoma.

An update to the phase II study of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma showed promising overall response rate, according to a press release from ADC Therapeutics SA.

A new drug application for selinexor has been submitted to the FDA for the treatment of patients with relapsed or refractory diffuse large b-cell lymphoma who have had at least 2 prior multi-drug therapies,and who are ineligible for stem cell transplantation, including chimeric antigen receptor T-cell therapy, according to a press release from Karypharm Therapeutics, developer of selinexor.<br /> &nbsp;

The phase III B-MIND study of the investigational humanized Fc-engineered monoclonal antibody, tafasitamab plus bendamustine versus rituximab plus bendamustine for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, has passed the pre-planned, event-driven interim analysis for futility, resulting in a recommendation to increase the number of study participants from 330 to 450, according to a press release from MorphoSys.

Non-Hodgkin Lymphoma

Topline results from Re-MIND, an observational retrospective study, demonstrated that the combination of tafasitamab with lenalidomide had a statistically significant and superior objective response rate compared with lenalidomide monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for high-dose chemotherapy and stem cell transplant, announced MorphoSys AG, the manufacturer of tafasitamab, in a press release.

Emerging from the recent 2019 World Conference on Lung Cancer&nbsp;are several notable developments, Robert L. Ferris, MD, PhD, wrote in this issue of&nbsp;<em>Targeted Therapies in Oncology.&nbsp;</em>

Barbara Pro, MD, spoke with a group of physicians during a <em>Targeted Oncology </em>live case-based peer perspectives discussion about the diagnosis, prognosis, and treatment of patients with Hodgkin lymphoma based on the case&nbsp;of a young woman with classic Hodgkin lymphoma.

Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.

In an interview with&nbsp;<em>Targeted Oncology</em>, Marcelo C. Pasquini, MD, discussed the importance of obtaining real-world data and establishing registries for collecting patient outcomes, and how real-world data compare with data from pivotal trials. He also explained the challenges with accessibility to CAR T-cell therapies.